Have you received a notification from your insurance carrier that coverage of your specialty medication is changing? If so, you aren’t the only one. Many of my patients who are on biologics have been informed by their insurer that they are now required to switch to a biosimilar. I know ...

When biosimilars first entered the market five years ago, I was excited about new treatment options for patients and for more competition to be created in the market. In the years since, we have seen seven biosimilars approved by the U.S. Food & Drug Administration for IBD indicatio...